HighTower Advisors
MRNA icon

HighTower Advisors’s Moderna MRNA Stock Holding History

HighTower Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.8M Buy
55,953
+24,131
+76% +$2.6M 0.01% 905
2026
Q2 		$2.23M Buy
31,822
+5,647
+22% +$292K ﹤0.01% 1698
2026
Q1 		$1.33M Buy
26,175
+6,502
+33% +$303K ﹤0.01% 2001
2025
Q4 		$580K Sell
19,673
-17,127
-47% -$465K ﹤0.01% 2500
2025
Q3 		$951K Sell
36,800
-3,429
-9% -$95.7K ﹤0.01% 2132
2025
Q2 		$1.11M Sell
40,229
-310
-0.8% -$8.16K ﹤0.01% 1947
2025
Q1 		$1.15M Buy
40,539
+7,800
+24% +$277K ﹤0.01% 1874
2024
Q4 		$1.36M Sell
32,739
-2,000
-6% -$95.6K ﹤0.01% 1766
2024
Q3 		$2.28M Sell
34,739
-14,040
-29% -$1.29M ﹤0.01% 1435
2024
Q2 		$5.77M Sell
48,779
-13,397
-22% -$1.7M 0.01% 950
2024
Q1 		$6.62M Buy
62,176
+4,340
+8% +$437K 0.01% 848
2023
Q4 		$5.67M Sell
57,836
-1,493
-3% -$126K 0.01% 912
2023
Q3 		$6.11M Buy
59,329
+15,077
+34% +$1.68M 0.01% 842
2023
Q2 		$5.34M Buy
44,252
+6,557
+17% +$875K 0.01% 873
2023
Q1 		$5.79M Sell
37,695
-1,876
-5% -$309K 0.01% 792
2022
Q4 		$7.11M Sell
39,571
-32,773
-45% -$5.36M 0.02% 712
2022
Q3 		$8.55M Buy
72,344
+9,227
+15% +$1.4M 0.02% 617
2022
Q2 		$9.02M Buy
63,117
+31,367
+99% +$4.48M 0.02% 607
2022
Q1 		$5.46M Sell
31,750
-7,540
-19% -$1.27M 0.01% 845
2021
Q4 		$10M Sell
39,290
-11,177
-22% -$3.27M 0.02% 608
2021
Q3 		$19.4M Sell
50,467
-3,419
-6% -$1.26M 0.05% 351
2021
Q2 		$12.7M Buy
53,886
+8,940
+20% +$1.6M 0.04% 441
2021
Q1 		$5.89M Buy
44,946
+11,438
+34% +$1.66M 0.02% 685
2020
Q4 		$3.49M Sell
33,508
-2,598
-7% -$263K 0.01% 698
2020
Q3 		$2.55M Buy
36,106
+13,959
+63% +$973K 0.01% 787
2020
Q2 		$1.42M Buy
22,147
+11,740
+113% +$643K 0.01% 952
2020
Q1 		$312K Buy
+10,407
New +$239K ﹤0.01% 1543

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return

HighTower Advisors's MRNA Position: Q3 2026 in Review

HighTower Advisors increased its Moderna (MRNA) stake by 76% in Q3 2026, buying an estimated $2.6M and bringing the position to 55,953 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #905.

HighTower Advisors first reported a position in MRNA in Q1 2020 and has held it in 27 quarters since. The position peaked at $19.4M in Q3 2021. 578 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • HighTower Advisors held 55,953 shares of Moderna worth $10.8M as of Q3 2026.
  • HighTower Advisors bought 24,131 Moderna shares in Q3 2026, an estimated $2.6M.
  • Moderna made up 0.01% of HighTower Advisors's portfolio in Q3 2026, its #905 holding.
  • HighTower Advisors first reported a position in Moderna in Q1 2020 and has held it in 27 quarters since.
  • HighTower Advisors's Moderna position peaked at $19.4M in Q3 2021.
  • 578 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.